Abstract Number: 2355 • 2013 ACR/ARHP Annual Meeting
Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Against The IL-6 Receptor Alpha: Using Acute Phase Reactants, Efficacy and Safety Parameters To Inform Phase 3 Dose Selection
Background/Purpose: Sarilumab (SAR) is a fully human mAb directed against IL-6Rα. In phase 2 MOBILITY Part A (NCT01061736), SAR administered SC plus MTX (methotrexate 10-25…Abstract Number: 2356 • 2013 ACR/ARHP Annual Meeting
Soluble Interleukin-2 Receptor Levels and The CD4/CD8 Ratio As Predictors Of The Efficacy Of Abatacept In Biologics-naïve Rheumatoid Arthritis Patients
Background/Purpose: Abatacept (ABT) is a recombinant fusion protein consisting of the extracellular domain of human CTLA-4, binding to CD80/86 on antigen presenting cells and thereby…Abstract Number: 2357 • 2013 ACR/ARHP Annual Meeting
Confounding By Indication Distorts The Relationship Between Steroid Use and Cardiovascular Disease In Rheumatoid Arthritis
Background/Purpose: Glucocorticoids (GC) are among the most effective drugs in rheumatoid arthritis (RA), but concerns over long-term side effects have not been resolved. Recent studies…Abstract Number: 2358 • 2013 ACR/ARHP Annual Meeting
Sarilumab, a Subcutaneously Administered, Fully Human Monoclonal Antibody Inhibitor Of The IL-6 Receptor Alpha: 12 Week Infection Rates By Level Of Circulating Neutrophils In Rheumatoid Arthritis and Ankylosing Spondylitis
Background/Purpose: Sarilumab is a human monoclonal antibody directed against the alpha subunit of the IL-6 receptor (IL-6Rα). IL-6 blockade is associated with a reduction in…Abstract Number: 2359 • 2013 ACR/ARHP Annual Meeting
Impact Of Etanercept-Methotrexate Treatment Withdrawal On Patient-Reported Outcomes In Patients With Early Rheumatoid Arthritis (PRIZE Trial)
Background/Purpose: Active rheumatoid arthritis (RA) is commonly associated with impairment of physical function and health-related quality of life (QoL), as well as work disability. The…Abstract Number: 2360 • 2013 ACR/ARHP Annual Meeting
Incidence Of Diabetes and Effect Of Etanercept and Adalimumab On HbA1c Over 1 Year: Data From a Randomised Trial In Patients With Rheumatoid Arthritis
Background/Purpose: Inflammation such as that which occurs in rheumatoid arthritis (RA) is associated with insulin resistance and risk of diabetes mellitus (DM). Some DMARDs including…Abstract Number: 2361 • 2013 ACR/ARHP Annual Meeting
Pharmacokinetic and Pharmacodynamic Characterization Of a Dissociated Agonist Of Glucocorticoid Receptor, Following Multiple Dose Administration In Healthy Japanese Adult Subjects
Background/Purpose: PF-04171327 is a prodrug of PF-00251802, a dissociated agonist of the glucocorticoid receptor (DAGR) and being developed as treatment for Rheumatoid Arthritis. The objective…Abstract Number: 2362 • 2013 ACR/ARHP Annual Meeting
Incidence Of Adverse Events In Patients With Rheumatoid Arthritis and Spondyloarthritis Exposed To Anti-TNF Therapy. Data From The Brazilian Registry For Monitoring Of Biologic Therapies In Rheumatic Diseases (BiobadaBrasil)
Background/Purpose: The safety profile of a-TNF biologic drugs might have substantial regional differences due to geographic and socio economic factors and to epidemiology of infectious…Abstract Number: 2363 • 2013 ACR/ARHP Annual Meeting
Positivity Of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Is Associated With The Response Rate Of Infliximab, But Not Tocilizumab, In Treatment Of Rheumatoid Arthritis
Background/Purpose: Recent reports have shown that positivity for rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) can influence the efficacy of rheumatoid arthritis (RA) treatment.…Abstract Number: 2364 • 2013 ACR/ARHP Annual Meeting
Baseline Procalcitonin Levels Are Predictive Marker Of Remission In Biologic naïve Patients With Rheumatoid Arthritis Treated With Tocilizumab: Result From 24 Weeks Of Follow-Up
Background/Purpose: , :Procalcitonin(PCT) is a useful marker of infection. PCT-mRNA increases expression from peripheral blood mononuclear cells by stimulation of a pro inflammatory cytokine, IL-6…Abstract Number: 2365 • 2013 ACR/ARHP Annual Meeting
Concomitant Methotrexate Did Not Affect Discontinuation Rate Of Etanercept Due To Ineffectiveness: Six-Year Results From Japanese Multicenter Registry System
Background/Purpose: In the last decade, treatment with tumor necrosis factor (TNF) inhibitors has significantly improved the outcome in patients with rheumatoid arthritis (RA). Recent studies…Abstract Number: 2366 • 2013 ACR/ARHP Annual Meeting
Economic Impact Of Adalimumab Treatment In Japanese Patients With Rheumatoid Arthritis: Analysis Of 24 Weeks Data From The Anouveau Study
Background/Purpose: Patients with rheumatoid arthritis (RA) incur higher costs owing to missed work days and short-time disability. Although methotrexate combined with adalimumab (ADA) provides comprehensive…Abstract Number: 2367 • 2013 ACR/ARHP Annual Meeting
Discontinuation Of Biological Therapy Due To Adverse Drug Reactions In Rheumatoid Arthritis Patients: 12 Years Follow-Up
Background/Purpose: To describe in a cohort of rheumatoid arthritis (RA) patients followed up to 12 years, in standard clinical practice, the rate of biological agents…Abstract Number: 2368 • 2013 ACR/ARHP Annual Meeting
Tocilizumab Efficiently Halts Radiographic Progression In Patients With Rheumatoid Arthritis and Swollen Joint Counts Within a Year Predict Long-Term Radiographic Outcomes: Three Year Results From Michinoku Tocilizumab Study Group
Background/Purpose: One of the important therapeutic goals in patients with rheumatoid arthritis (RA) is to halt radiographic progression. Tocilizumab (TCZ), an IL-6 receptor antibody, has…Abstract Number: 2369 • 2013 ACR/ARHP Annual Meeting
Long-Term Outcome Of Infliximab Therapy In Rheumatoid Arthritis Patients: Results From Japanese Multicenter Registry System
Background/Purpose: After demonstration of effectiveness of anti-tumor necrosis factor (TNF) agents in patients with rheumatoid arthritis (RA), their use has become common practice in treating…
ACR Meeting Abstracts